Belite Bio Inc
BLTEHealthcare|Biotechnology|USA
$149.25
-3.91 (-2.55%)
Tangible Book
$19.85
Upcoming Data Readouts (2)
Jun 2027
Est. completion
P3Geographic Atrophy
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
NCT05949593n=429
Feb 2028
Est. completion
P2P3STGD1
A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease
NCT06388083n=60